{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:11:44Z","timestamp":1793639504923,"version":"4.5.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI157758"],"award-info":[{"award-number":["R01-AI157758"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32-AI007001"],"award-info":[{"award-number":["T32-AI007001"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30-AI50410"],"award-info":[{"award-number":["P30-AI50410"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Division"},{"name":"of Acquired Immunodeficiency Syndrome","award":["R01-AI062333"],"award-info":[{"award-number":["R01-AI062333"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01-AI64002"],"award-info":[{"award-number":["U01-AI64002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While noninferiority of tenofovir alafenamide and emtricitabine (TAF\/FTC) as preexposure prophylaxis (PrEP) for the prevention of human immunodeficiency virus (HIV) has been shown, interest remains in its efficacy relative to placebo. We estimate the efficacy of TAF\/FTC PrEP versus placebo for the prevention of HIV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from the DISCOVER and iPrEx trials to compare TAF\/FTC to placebo. DISCOVER was a noninferiority trial conducted from 2016 to 2017. iPrEx was a placebo-controlled trial conducted from 2007 to 2009. Inverse probability weights were used to standardize the iPrEx participants to the distribution of demographics and risk factors in the DISCOVER trial. To check the comparison, we evaluated whether risk of HIV infection in the shared tenofovir disoproxil fumarate and emtricitabine (TDF\/FTC) arms was similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Notable differences in demographics and risk factors occurred between trials. After standardization, the difference in risk of HIV infection between the TDF\/FTC arms was near zero. The risk of HIV with TAF\/FTC was 5.8 percentage points lower (95% confidence interval [CI], \u22122.0% to \u22129.6%) or 12.5-fold lower (95% CI, .02 to .31) than placebo standardized to the DISCOVER population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was a reduction in HIV infection with TAF\/FTC versus placebo across 96 weeks of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT02842086 and NCT00458393.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiad507","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T16:59:35Z","timestamp":1699894775000},"page":"1123-1130","source":"Crossref","is-referenced-by-count":4,"title":["HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo"],"prefix":"10.1093","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9932-1095","authenticated-orcid":false,"given":"Paul N","family":"Zivich","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"},{"name":"Institute of Global Health and Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-335X","authenticated-orcid":false,"given":"Jessie K","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5888-1419","authenticated-orcid":false,"given":"David V","family":"Glidden","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moupali","family":"Das","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-4047","authenticated-orcid":false,"given":"Bonnie E","family":"Shook-Sa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwu","family":"Shao","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha L","family":"Mehrotra","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California , San Francisco, California , USA"},{"name":"Gilead Sciences , Foster City, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-1552","authenticated-orcid":false,"given":"Adaora A","family":"Adimora","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"},{"name":"Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-0644","authenticated-orcid":false,"given":"Joseph J","family":"Eron","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"},{"name":"Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"2024041213294463000_jiad507-B1","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"2024041213294463000_jiad507-B2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"2024041213294463000_jiad507-B3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"2024041213294463000_jiad507-B4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"2024041213294463000_jiad507-B5","doi-asserted-by":"crossref","DOI":"10.1177\/2325958220919231","article-title":"A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide","volume":"19","author":"Wassner","year":"2020","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2024041213294463000_jiad507-B6","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1097\/QAD.0000000000003062","article-title":"Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine\/tenofovir alafenamide vs. emtricitabine\/tenofovir disoproxil fumarate","volume":"35","author":"Yager","year":"2021","journal-title":"AIDS"},{"key":"2024041213294463000_jiad507-B7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"2024041213294463000_jiad507-B8","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Ogbuagu","year":"2021","journal-title":"Lancet HIV"},{"key":"2024041213294463000_jiad507-B9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.recesp.2013.11.016","article-title":"The transitive property across randomized controlled trials: if B is better than A, and C is better than B, will C be better than A?","volume":"67","author":"Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Rev Esp Cardiol"},{"key":"2024041213294463000_jiad507-B10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/sim.2855","article-title":"Current issues in non-inferiority trials","volume":"27","author":"Fleming","year":"2008","journal-title":"Stat Med"},{"key":"2024041213294463000_jiad507-B11","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2206.04445","article-title":"Bridged treatment comparisons: an illustrative application in HIV treatment","author":"Zivich","year":"2022","journal-title":"arXiv"},{"key":"2024041213294463000_jiad507-B12","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1002\/sim.8963","article-title":"Fusion designs and estimators for treatment effects","volume":"40","author":"Breskin","year":"2021","journal-title":"Stat Med"},{"key":"2024041213294463000_jiad507-B13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/biom.12388","article-title":"New methods for treatment effect calibration, with applications to non-inferiority trials","volume":"72","author":"Zhang","year":"2016","journal-title":"Biometrics"},{"key":"2024041213294463000_jiad507-B14","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2305.00845","article-title":"Fusing trial data for treatment comparisons: single versus multi-span bridging","author":"Shook-Sa","year":"2023","journal-title":"arXiv"},{"key":"2024041213294463000_jiad507-B15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000216","article-title":"Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection","volume":"66","author":"Amico","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024041213294463000_jiad507-B16","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/aje\/kwx164","article-title":"Transportability of trial results using inverse odds of sampling weights","volume":"186","author":"Westreich","year":"2017","journal-title":"Am J Epidemiol"},{"key":"2024041213294463000_jiad507-B17","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2024041213294463000_jiad507-B18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.0006-341X.2000.00779.x","article-title":"Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests","volume":"56","author":"Robins","year":"2000","journal-title":"Biometrics"},{"key":"2024041213294463000_jiad507-B19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Stat Method"},{"key":"2024041213294463000_jiad507-B20","first-page":"216","article-title":"Discussion of the paper by D. R. Cox","volume":"34","author":"Breslow","year":"1972","journal-title":"J R Stat Soc Series B Stat Method"},{"key":"2024041213294463000_jiad507-B21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/EDE.0b013e31815be045","article-title":"The Breslow estimator of the nonparametric baseline survivor function in Cox's regression model: some heuristics","volume":"19","author":"Hanley","year":"2008","journal-title":"Epidemiology"},{"key":"2024041213294463000_jiad507-B22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with NumPy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"key":"2024041213294463000_jiad507-B23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"},{"key":"2024041213294463000_jiad507-B24","first-page":"56","author":"McKinney","year":"2010"},{"key":"2024041213294463000_jiad507-B25","first-page":"92","author":"Seabold","year":"2010"},{"key":"2024041213294463000_jiad507-B26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput Sci Eng"},{"key":"2024041213294463000_jiad507-B27","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1093\/aje\/kwab231","article-title":"Twister plots for time-to-event studies","volume":"190","author":"Zivich","year":"2021","journal-title":"Am J Epidemiol"},{"key":"2024041213294463000_jiad507-B28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2024041213294463000_jiad507-B29","author":"Merck Sharp and Dohme LLC"},{"key":"2024041213294463000_jiad507-B30","author":"Gilead Sciences"},{"key":"2024041213294463000_jiad507-B31","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"key":"2024041213294463000_jiad507-B32","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/sim.9296","article-title":"Statistical considerations for cross-sectional HIV incidence estimation based on recency test","volume":"41","author":"Gao","year":"2022","journal-title":"Stat Med"},{"key":"2024041213294463000_jiad507-B33","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1016\/S2352-3018(20)30192-2","article-title":"A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial","volume":"7","author":"Glidden","year":"2020","journal-title":"Lancet HIV"},{"key":"2024041213294463000_jiad507-B34","doi-asserted-by":"crossref","first-page":"e25744","DOI":"10.1002\/jia2.25744","article-title":"Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial","volume":"24","author":"Glidden","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2024041213294463000_jiad507-B35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/aje\/kwv200","article-title":"Invited commentary: every good randomization deserves observation","volume":"182","author":"Westreich","year":"2015","journal-title":"Am J Epidemiol"},{"key":"2024041213294463000_jiad507-B36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/QAI.0000000000000351","article-title":"Patterns and correlates of PrEP drug detection among MSM and transgender women in the global iPrEx study","volume":"67","author":"Liu","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024041213294463000_jiad507-B37","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s10461-017-1958-4","article-title":"Predictors of over-reporting HIV pre-exposure prophylaxis (PrEP) adherence among young men who have sex with men (YMSM) in self-reported versus biomarker data","volume":"22","author":"Baker","year":"2018","journal-title":"AIDS Behav"},{"key":"2024041213294463000_jiad507-B38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/QAI.0000000000002003","article-title":"Predictors of long-term HIV pre-exposure prophylaxis adherence after study participation in men who have sex with men","volume":"81","author":"Hoenigl","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024041213294463000_jiad507-B39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15381501.2021.1956666","article-title":"Factors associated with PrEP adherence among MSM living in Jackson, Mississippi","volume":"20","author":"Whiteley","year":"2021","journal-title":"J HIV AIDS Soc Serv"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad507\/53971507\/jiad507.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/4\/1123\/57223203\/jiad507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/4\/1123\/57223203\/jiad507.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:01:42Z","timestamp":1730487702000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/4\/1123\/7424314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,16]]},"published-print":{"date-parts":[[2024,4,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad507","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,15]]},"published":{"date-parts":[[2023,11,16]]}}}